摘要
目的评估显色原位杂交(CISH)技术在检测乳腺癌标本中 HER2基因扩增的应用价值。方法分别采用免疫组织化学(IHC)En Vision 和 CISH 两种方法,检测165例乳腺癌中 HER2蛋白表达及 HER2基因扩增的情况。结果 (1)IHC 检测 HER2蛋白表达阴性者107例,表达阳性1+者24例,CISH 均未检测到 HER2基因扩增;(2)IHC 检测 HER2表达3+者22例,CISH 检测中21例呈现 HER2基因的高倍扩增,仪1例呈低倍扩增,HER2基因高倍扩增及其蛋白表达之间的符合率为95.5%;(3)IHC 检测 HER2表达2+者12例,CISH 检测有3例 HER2基因呈高倍扩增,6例呈低倍扩增,3例无扩增。结论 CISH 在检测 HER2基因扩增与 IHC 检测的结果具有较高的一致性和敏感性,可以作为一种检测乳腺癌 HER2基因状况的方法。
Objective To evaluate the sensitivity and specificity of chromogenic in-situ hybridization （CISH） in detecting HER2 gene amplification in breast carcinomas. Methods HER2 oncogene amplification and its protein expression in 165 cases of breast carcinoma were investigated by immunohistochemistry （ IHC ） and CISH. Results （ 1 ） CISH did not detect HER2 gene amplification in 107 cases of IHC negative tumors and 24 cases of IHC 1 ＋ tumors. （2） CISH identified high copy numbers of HER2 gene amplification in 21/22 （95.5%） cases with IHC 3 ＋. （3） In 12 HIC 2 ＋ cases, CISH identified 3 cases of high copy number amplification, 6 cases of low copy number amplification and 3 cases without amplification. Conclusions HER2 gene amplification detection by CISH is highly sensitive and has a high concordance with IHC detection of the protein expression. It is concluded that CISH is a tool to evaluate HER2 gene status in breast cancer and can be an implement in conventional pathology laboratories.
出处
《中华病理学杂志》
CAS
CSCD
北大核心
2007年第7期457-460,共4页
Chinese Journal of Pathology
